Limitations of screening for occult cancer in patients with idiopathic venous thromboembolism

Netherlands Journal of Medicine

Volumn 70, Issue 7, 2012, Pages 311-317

  Kleinjan, A ^a   van Doormaal, F F ^a   Prins, M H ^b   Buller H R ^a   Otten, J M M B ^c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Costs; Idiopathic venous thromboembolism; Occult cancer; Whole body CT screening

Indexed keywords

ARTICLE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FALSE POSITIVE RESULT; FEMALE; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; IDIOPATHIC DISEASE; IDIOPATHIC VENOUS THROMBOEMBOLISM; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOEMBOLISM;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MAMMOGRAPHY; MASS SCREENING; NEOPLASMS, UNKNOWN PRIMARY; NETHERLANDS; PREDICTIVE VALUE OF TESTS; RADIOGRAPHY, ABDOMINAL; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; VENOUS THROMBOEMBOLISM;

EID: 84866368784     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Lee AY. Screening for occult cancer in patients with idiopathic venous thromboembolism: no. J Thromb Haemost. 2003;1:2273-4.
2. Piccioli A, Prandoni P. Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost. 2003;1:2271-2.
3. Monreal M, Lensing AW, Prins MH, et al. Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost. 2004;2:876-81.
4. Carrier M, Le Gal G, Wells PS, Fergusson D, Ramsay T, Rodger MA. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism? Ann Intern Med. 2008;149:323-33.
5. Rondina MT, Wanner N, Pendleton RC, et al. A pilot study utilizing whole body 18 F-FDG-PET/CT as a comprehensive screening strategy for occult malignancy in patients with unprovoked venous thromboembolism. Thromb Res. 2012;129:22-7.
6. Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost. 2004;2:884-9.
7. Di Nisio M, Otten HM, Piccioli A, et al. Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost. 2005;3:2391-6.
8. van Doormaal FF, Terpstra W, Van Der Griend R, et al. Is extensive screening for cancer in idiopathic venous thromboembolism warranted? J Thromb Haemost. 2011;9:79-84.
9. Grosse SD, Teutsch SM, Haddix AC. Lessons from cost-effectiveness research for United States public health policy. Annu Rev Public Health. 2007;28:365-91.
10. Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med. 2010;152:505-12.
11. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
12. US Food and Drug Association. Whole body CT screening. 5-6-2009. 8-6-2009. Ref Type: Internet Communication.
13. Salz T, Richman AR, Brewer NT. Meta-analyses of the effect of false-positive mammograms on generic and specifc psychosocial outcomes. Psychooncology. 2010;19:1026-34.